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Abstract
Bordetella pertussis filamentous hemagglutinin (FHA) is a surface-associated and secreted protein that serves as a crucial
adherence factor, and displays immunomodulatory activity in human peripheral blood mononuclear cells (PBMCs). In order
to appreciate more fully the role of secreted FHA in pathogenesis, we analyzed FHA-induced changes in genome-wide
transcript abundance in human PBMCs. Among the 683 known unique genes with greater than 3-fold change in transcript
abundance following FHA treatment, 125 (18.3%) were identified as interferon (IFN)-regulated. Among the latter group were
genes encoding several members of the IFN type I response, as well as 3 key components of the ISGylation pathway. Using
real-time RT-PCR, we confirmed FHA-associated increases in transcript abundance for the genes encoding ubiquitin-like
protein, ISG15, and its specific protease USP18. Western-blot analysis demonstrated the presence of both, free ISG15 and
several ISGylated conjugates in FHA-stimulated PBMC lysates, but not in unstimulated cells. Intracellular FACS analysis
provided evidence that monocytes and a natural killer-enriched cell population were the primary producers of ISG15 in
PBMCs after FHA stimulation. Our data reveal previously-unrecognized effects of B. pertussis FHA on host IFN and ISGylation
responses, and suggest previously-unsuspected mechanisms by which FHA may alter the outcome of the host-pathogen
interaction.
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Introduction
Bordetella pertussis is a human restricted pathogen and the
causative agent of the acute respiratory disease, pertussis or
whooping cough. Despite the use of an effective vaccine since the
1940s, pertussis remains a major cause of childhood mortality
worldwide and has re-emerged in some highly vaccinated
populations [1,2]. B. pertussis colonizes the upper respiratory tract;
after attachment to the cilia of epithelial cells, it proliferates on the
ciliated mucosal surface, resulting in damage to the mucosa, influx
of inflammatory cells, and the shedding of cells into the lumen of
the respiratory tract. B. pertussis is primarily an extracellular
organism, but it may persist within leukocytes and epithelial cells
[3,4]. The infection process is mediated by several virulence
factors [5], most of which are tightly regulated by a two-
component signal transduction system, BvgAS [6].
A key BvgAS-regulated virulence factor is filamentous hemag-
glutinin (FHA), which plays a crucial role in mediating adherence
to eukaryotic cells [7]. Because of its immunogenicity and
immunoprotective activity, FHA is a component of most acellular
pertussis vaccines. FHA, encoded by fhaB, is synthesized as a
367 kDa precursor, FhaB, which undergoes extensive N- and C-
terminal modifications to form the mature 220 kDa FHA protein.
After transport across the cytoplasmic membrane by a Sec signal
peptide-dependent pathway, FhaB is secreted across the outer
membrane by the two-partner secretion system. During the
translocation process, approximately 130 kDa of the C terminus
is proteolytically cleaved by SphB1. While SphB1 contributes to
FHA release into the extracellular milieu, it is not required, and
the mechanism by which FHA is released from the cell surface
remains unclear [8]. Another important unanswered question
addressed by this work in particular, concerns the role of the
released form of FHA in pathogenesis [8].
In vitro studies have suggested that FHA functions as an adhesin
and several binding domains have been identified: an Arg-Gly-Asp
(RGD) triplet [9], a carbohydrate recognition domain (CRD) for
binding to ciliated respiratory epithelial cells and macrophages [10],
and a lectin-like domain for binding to heparin and other sulphated
carbohydrates on non-epithelialcells [11]. FHA also exhibits several
immunomodulatory properties, including its ability to interfere with
NF-kB activation [12] and to induce the secretion of both pro- and
anti-inflammatory cytokines by macrophages [13,14].
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primarily because a natural nonhuman host for B. pertussis does not
exist, but also because of the complexity of this molecule and its
associated biological activities. In rabbit and mouse models of B.
pertussis infection, there are conflicting results regarding the role of
FHA in the persistence of bacteria in the lung. However, in a rat
model of natural B. bronchiseptica respiratory infection, FHA was
absolutely necessary, although not sufficient, for tracheal coloni-
zation [15]. The secreted form of FHA might facilitate dispersal of
bacteria from microcolonies and detachment from epithelial
surfaces, and thereby promote bacterial spread [16]. In addition,
B. bronchiseptica FHA may control the repertoire or abundance of
cytokines induced in the lungs of infected mice, as suggested by the
substantial inflammation induced by an fhaB null mutant strain, in
contrast to the mild inflammation induced by wild-type B.
bronchiseptica [17]. Because of the recently demonstrated functional
interchangeability of B. pertussis and B. bronchiseptica FHA [18], the
above findings are likely to apply to B. pertussis FHA as well.
The analysis of genome-wide host transcriptional responses is
one approach for exploring and further characterizing complex
host-pathogen interactions. During the past decade, this approach
has been successfully employed to study the host response to a
broad range of pathogens and virulence factors [19]. Although
exposure to pathogens induces a broadly conserved host cell
transcriptional program [20,21], specific profiles have been
observed for individual virulence factors, perhaps because different
microbial products are detected by different combinations of
receptors, such as Toll-like receptors (TLRs) [22]. Activation of
TLRs leads to the production of various cytokines and
chemokines, including type I interferons (IFNs). Type I IFNs
(IFN-a, IFN-b, IFN-e, IFN-k, and IFN-v) are potent immunor-
egulators, responsible for activating key components of the innate
and adaptive immune system. IFN-induced activation of the JAK/
STAT pathway triggers the transcription of hundreds of interferon
stimulated genes (ISGs). ISG15, one of the earliest and most
strongly induced ISGs, is the oldest known member of the
ubiquitin-like (UbL) modifier polypeptides and was described
more than 30 years ago [23]. However, it is only recently that
interest has focused on understanding this UbL polypeptide with
the unique properties of acting both as a modifier of protein
function and as a cytokine that modulates immune responses [24].
ISGylation, the process by which ISG15 is conjugated to a target
protein, involves a set of enzymes analogous to the ubiquitin
modification system: the ubiquitin activating enzyme E1-like
(UBE1L), the E2 conjugating enzyme UBC8, the putative ISG15
E3 ligase, and the ISG15 deconjugating enzyme UBP43 (USP18)
[25]. Several hundreds of target proteins have been identified [26–
28]. Recently, a novel role of ISG15 in protecting cells from
infection by several viruses has become evident [29–33]. The role
of ISG15 and the ISGylation pathway in defence against bacterial
infection has not been described in detail but it is of great interest
due to the fact that 1) ISG15 is induced upon contact with bacteria
or bacterial products [20,34,35] and 2) type I IFNs play an
important role in the host response to bacterial infections [36].
The goal of this study was to characterize the effects of purified
B. pertussis FHA on human cells by examining the genome-wide
transcriptional response of human peripheral blood mononuclear
cells (PBMCs). Such an investigation might enhance our
understanding of the contributions of free, soluble FHA in the
pathogenesis of Bordetella infection. One would expect resident
and recruited mucosal mononuclear leukocytes to encounter
secreted forms of FHA during the course of disease. We
demonstrate that FHA is a strong inducer of the IFN response,
including IFN type I. In addition, purified FHA enhances
expression of at least three members of the ISGylation pathway:
ISG15, USP18, and UBE1L. These results suggest new putative
mechanisms by which this key bacterial adhesin modulates the
host immune response, mechanisms that may be relevant both in
the context of natural infection and following administration of
FHA-containing Bordetella vaccines.
Results
Genome-wide responses of human PBMCs to purified B.
pertussis FHA
To gain insight into the effect of cell-free FHA on host
responses, we characterized the genome-wide gene expression
program in human PBMCs stimulated with purified FHA. This
analysis was undertaken with four different FHA preparations,
purified from four different B. pertussis strains (two clinical isolates
and two lab strains), in order to recognize conserved activities
associated with this protein and avoid strain-specific biases. Prior
to FHA preparation, all genes associated with pertussis toxin (PT)
expression were deleted from the strains, so that PT co-
purification would be eliminated. One of the preparations,
FHA-1, had been used previously to study the immunological
properties of FHA [12,13]. While the presence of trace amounts of
non-FHA contaminants in the preparations could not be ruled out,
even after verification of the purity by Coomassie blue staining of
protein-loaded acrylamide gels and Western immunoblot analysis
(Fig. S1), the use of several independent preparations with
presumably different contaminants in different, albeit low
amounts, greatly strengthened the likelihood that the dominant,
conserved activities and responses elicited by these preparations
are attributable to FHA.
Cultures of 3610
6 PBMCs were stimulated for 0.5, 2, 4, and
6 hours with 5 mg/ml of each purified B. pertussis FHA
preparation. At that concentration, FHA-1 is known to induce
both pro-inflammatory and pro-apoptotic responses in human
cells [13] and to modulate the NF-kB pathway [12]. Control
PBMC cultures were simultaneously treated with similar volumes
of elution buffers (‘‘Mock-1’’ and ‘‘Mock-2’’), and sampled at the
same time points. A total of 23 samples were analysed,
representing a total of 23 arrays. Among the 25,867 microarray
elements whose hybridization signals were measured with
confidence (Materials & Methods), 1,235 elements exhibited at
least a 3-fold change in transcript abundance relative to the
untreated samples in at least 3 out of 23 arrays. (The microarray
data from the FHA-4 stimulated cells at the 4 h time point were
not included in the analysis because of poor microarray signal
quality.) The 683 known unique genes represented by these 1,235
elements were considered to be FHA-responsive and were
organized by hierarchical clustering (Fig. 1A). All four FHA
preparations induced very similar gene expression profiles,
suggesting minimal functional differences between FHA protein
from different B. pertussis strain backgrounds.
FHA-responsive genes could be assigned to two major classes:
an FHA-activated cluster comprising 817 elements (419 known
unique genes; Table S1) and a FHA-repressed cluster comprising
418 elements (254 known unique genes; Table S2). The genes in
the activation cluster could be further subdivided into three
groups, according to their temporal expression profile (Fig. 1A).
Group I contained genes whose expression was strongly up-
regulated at 0.5 hour, but was lower at subsequent time points.
Group II included genes whose expression was induced at
0.5 hour and remained elevated throughout the experiment. In
Group III, the largest group, up-regulation occurred later, starting
at 2 or 4 hours after FHA treatment.
B. pertussis FHA and IFN Response
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including JUN, JUNB, EGR, MAPK9, IRF1, STAT4, and
ATF3, were induced within 30 minutes of FHA exposure.
Members of the NF-kB pathway, including the transcriptional
regulators NFKB1 and NFKB2 and the inhibitor NFKBIA,
were also up-regulated by FHA treatment. As expected, the
expression of several targets of this pathway was also increased,
including genes encoding cytokines (TNF, IL1A, IL1B, IL6,
and LTA), chemokines (IL8, SCYA2/CCL2, and SCYB11/
CCL11), adhesion molecules (ICAM1), pro-inflammatory
enzymes (PTGS2/COX2), and kinases (PRKR/EIF2AK2,
IKBKG, MAP3K8).
Genes encoding cytokines and chemokines were some of the
most strongly FHA-induced loci: among the 20 unique genes up-
regulated at least 16-fold compared to unstimulated cells, 8
encoded proteins that belonged to this category (data not shown).
This result suggested that FHA is a strong pro-inflammatory
stimulus, and was confirmed by measuring the levels of TNF-a,
IL-1b, IL-6, and IL-8 protein in the supernatant of FHA-exposed
PBMCs (Fig. 1B). We stimulated 2610
6 cells from each of 4
Figure 1. Overview of gene expression and pro-inflammatory cytokine response in FHA-treated PBMCs. (A) PBMCs were stimulated for
0.5, 2, 4, and 6 hrs (time course represented by the triangles) with FHA-1, FHA-2, and FHA-3 at 5 mg/ml, and for 0.5, 2, and 6 hrs with FHA-4 at the
same concentration. As a control, cells were treated with similar volumes of the corresponding elution buffers (‘‘Mock-1’’ and ‘‘Mock-2’’). A total of
1,235 elements displayed a $3-fold change in transcript abundance in at least 3 arrays; they are represented in a hierarchical cluster format. Data
from individual elements or genes are represented as a single row, and different time points in the time courses are shown as columns. Red and
green denote expression levels greater than or less than, respectively, baseline values (average of four untreated samples taken at time zero). The
intensity of the color reflects the magnitude of the change from baseline. Gray color represents missing or excluded data. (B) PBMCs, isolated from
four healthy individuals (donors 1–4), were stimulated with FHA (FHA-1, -2, or -3) at 5 mg/ml or EcLPS at 1 mg/ml, or were untreated. After 8 hrs (IL-8)
and 24 hrs (TNF-a, IL-1b, and IL-6) of exposure, the supernatants were collected and analyzed. Data were obtained from two independent
experiments, one experiment in which cells were treated for 8 hrs and one experiment in which cells were treated for 24 hrs.
doi:10.1371/journal.pone.0027535.g001
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FHA-3) or 1 mg/ml E. coli lipopolysaccharide (EcLPS) for 8 or
24 hours. We confirmed increased levels of TNF-a (401682 and
260 pg/ml for FHA-treated [n=8] and mock-treated [n=4]
samples, respectively), IL-1b (325674 and 49628 pg/ml for
FHA-treated [n=8] and mock-treated [n=4] samples, respec-
tively), IL-8 (26,29266,243 and 1,9486898 pg/ml for FHA-
treated [n=4] and mock-treated [n=4] samples, respectively),
and IL-6 (6,6786844 and 119678 pg/ml for FHA-treated [n=8]
and mock-treated [n=4] samples, respectively), but noted some
inter-donor variation (results are given as average 6 SEM).
Following FHA exposure, genes involved in the negative
regulation of the inflammatory response through the JAK/STAT
pathway, such as SSI/SOCS, PIASY/PIAS4, and PTPs, were
induced. Regulation of the inflammatory response by FHA may
also occur through changes in expression of cytokine receptors, as
revealed by down-regulation of genes encoding cytokine receptors
IL13RA1 and IL18RAP and up-regulation of IL1 receptor
antagonist IL1RN.
FHA induces a host response distinct from that induced
by B. pertussis or its LPS
We evaluated the specificity of these gene expression responses
to FHA, and whether some responses might be attributable to
LPS. We compared our data (23 arrays, 1,235 elements) to
previously-published gene expression profiles from human PBMCs
exposed to heat-inactivated B. pertussis (strains BP338 and
Minnesota 1 [BpeMin1], ,1 bacterium per cell) or 1 mg/ml B.
pertussis LPS (BpeLPS) (16 arrays, 920 elements) [20]. The use of
identical strains and microarray platforms facilitated this compar-
ative analysis. A total of 143 elements (64 known unique genes)
with varying transcript abundance were identified in both our
1,235 and Boldrick’s 920 elements; they are represented in Fig. 2,
and organized by hierarchical clustering. Most of these genes were
similarly regulated (both up and down) in all treated samples. The
30 genes in the common activation cluster encode cytokines and
chemokines, adhesion molecules, transcription factors/regulators,
metabolism and signalling proteins, regulators of apoptosis, and
lymphocyte activation proteins. A total of 13 genes were activated
by FHA (‘‘FHA activation cluster’’) and not by heat-killed B.
pertussis and LPS. This cluster was composed primarily (9/13,
69%) of interferon (IFN)-stimulated genes: MX1, MX2, OAS1,
OAS2, OAS3, STAT1, STAF50/TRIM22, SCYB10/CXCL10,
and SSI1/SOCS1.
IFN responses dominate FHA-associated expression
profiles
We compared the 1,235 FHA-responsive elements presenting
$3-fold change in transcript abundance relative to the untreated
samples with lists of known IFN-a-, -b-, and -c-regulated genes
[36–40], in order to obtain a more complete transcript-associated
profile of the FHA-induced IFN response. This approach
identified 282 IFN-regulated elements (Table S3), representing a
total of 125 known unique genes, and suggested that FHA is a
strong inducer of the IFN type I response. FHA stimulated
increased levels of transcripts for genes associated with three well-
characterized IFN-induced antiviral mechanisms: the dsRNA-
activated protein kinase R (PRKR/EIF2AK2), the 29-59-oligoa-
denylate synthases (OAS), and the myxovirus resistance (MX)
proteins [40]. FHA also increased transcript levels for other genes
that encode proteins with potentially important antiviral activities
such as ISG20, guanylate-binding protein 1 (GBP1), promyelo-
Figure 2. FHA induces a distinct response as compared to heat-killed B. pertussis and its purified LPS. Data for the 1,235 FHA-responsive
elements from our 23 arrays were compared to data for the 920 elements previously described by Boldrick et al. from 16 arrays [20], whose expression
in PBMCs displayed a $2.5-fold change from baseline (t=0) in response to BpLPS (1 mg/ml) or to two heat-killed B. pertussis strains (BP338 and
Minnesota 1 [BpeMin1]). The 143 elements common to both data sets are represented in a hierarchical cluster format. Each time course is represented
by a triangle at the top of the Figure; the times of exposure are 0.5, 2, 4, and 6 hrs for all conditions except for FHA-4, in which the 4 hour time point
is missing. The genes represented by at least two non-identical elements on the arrays are indicated in bold.
doi:10.1371/journal.pone.0027535.g002
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1 (ADAR), and the adenosine deaminases (ADA).
FHA activates the host ISGylation pathway
The FHA-induced IFN type I response featured increased
transcript levels for genes encoding three key members of the
ISGylation pathway: ISG15, USP18, and UBE1L. ISG15, a
ubiquitin-like protein, is one of the IFN-stimulated genes (ISGs)
induced most rapidly and strongly by type I IFNs, as well as by
viral infection and LPS [24]. USP18, also known as UBP43, is an
ISG15-specific protease, removing ISG15 from target proteins
[41] and is a newly identified regulator of the IFN response [42].
Transcript levels for UBE1L, a gene that encodes the ISG15-
activating enzyme [43], increased $2.5-fold over levels in
untreated cells (data not shown).
The increased abundance of ISG15 and USP18 transcripts was
validated by RT-PCR with the same bulk RNA used for the
microarray analysis (data not shown). ISG15 and USP18
expression levels were further validated in an independent
experiment: PBMCs were stimulated for 1, 2, 4, 8, and 20 hrs
with 1,000 units (U)/ml IFN-a,1mg/ml EcLPS, 5 mg/ml FHA
(FHA-1 and FHA-2), or 0.1, 1, and 10 mg/ml BpeLPS. At each
time point, the culture supernatant was harvested to assess the
presence of IFN-a by ELISA, and the cells were collected to
perform RT-PCR with primers specific for ISG15 and USP18
(Fig. 3). FHA treatment induced the production of IFN-a as early
as 1 hr after exposure. Peak concentrations of IFN-a after FHA
stimulation were higher than after treatment with 10 mg/ml
BpeLPS (59563 vs. 135682 pg/ml after stimulation with FHA
and BpeLPS respectively) (Fig. 3C). Increased ISG15 transcript
abundance was detected 2 to 4 hrs after FHA treatment
(depending on the FHA preparation), with peak expression at
8 hours post-treatment (Fig. 3A). In cells stimulated with 1,000 U/
ml IFN-a, the increase in ISG15 transcript abundance began
earlier and was measurable (3661 –fold change relative to
untreated cells at time zero) after 1 hr of treatment. Similar
patterns were found for expression of USP18 (Fig. 3B). Compa-
rable results and similar kinetics were reproduced in an
independent experiment using differing concentrations (1, 5, and
10 mg/ml) of FHA (data not shown).
Enhanced ISG15 and USP18 expression might be solely
attributable to FHA-induced IFN-a release. However, our data
suggest that FHA might also stimulate expression of these two
genes through a mechanism independent of IFN-a, similar to the
genotoxic agent, camptothecin which activates ISG15 expression
in a p53-dependent, and IFN- and Jak-Stat-independent manner
[44]. Two arguments support this hypothesis. First, at 8 and 20 hrs
post-treatment, IFN-a concentrations were similar in the super-
natants of FHA- and IFN-a-treated cells (Fig. 3C). However, at the
same time points, relative levels of ISG15 and USP18 transcripts
were $1.8-fold higher in FHA-treated cells than in IFN-a-treated
cells. Similarly, at 4 hrs post-treatment, relative levels of ISG15
and USP18 transcripts were similar in FHA- and IFN-a-treated
cells, even though secreted IFN-a levels were four times lower in
FHA-treated cells. Second, although 5 mg/ml FHA and 10 mg/ml
BpeLPS induced similar levels of IFN-a between 1 and 4 hrs post-
treatment (Fig. 3C), FHA was associated with 4-fold higher levels
of ISG15 and USP18 transcripts (Figs. 3A, 3B). This observation
was confirmed in two other independent experiments (data not
shown). To rule out the possibility that BpeLPS had an inhibitory
effect on ISG15 and USP18 expression, BpeLPS (1 and 10 mg/ml)
was added to 5 mg/ml FHA, with no effect on ISG15 or USP18
expression levels (data not shown).
FHA induces the production of free ISG15 and several
ISGylated conjugates
Up-regulation of the ISGylation pathway, especially in the
context of a bacterial infection, is a relatively recent finding that
has not been well-characterized. We focused on our observation
that B. pertussis FHA affects the transcription of several members of
the ISGylation pathway, and in particular on ISG15, the
component of this pathway that becomes conjugated to cellular
target proteins [26] and that is associated with cytokine-like
immunomodulatory activities [45,46].
We first examined whether the increase in ISG15 transcript
abundance correlated with an increase in ISG15 and ISGylated
protein levels. PBMCs (5610
7) were stimulated with 1,000 U/ml
IFN-a,1mg/ml EcLPS, 10 mg/ml BpeLPS, or 5 mg/ml FHA-2.
After 20 hrs incubation, intracellular ISGylated proteins (Fig. 4A)
and free ISG15 (Fig. 4B) were detected by Western immunoblot
analysis using rabbit polyclonal and mouse monoclonal antibod-
ies, respectively. Compared to untreated cells, FHA-treated
cells produced larger quantities of ISGylated protein and free
ISG15, and similar quantities to those found in IFN- and EcLPS-
treated cells. No free ISG15 was detected in cells stimulated
with BpeLPS, although we cannot rule out the possibility that
some ISG15 protein might be expressed in both unstimulated
and BpeLPS-stimulated cells and would have been detected
with additional amounts of loaded protein. FHA-treated cells
contained an additional ISGylated protein, of ,130 kDa, not
detected in cells treated with LPS or IFN-a (Fig. 4A, arrow).
This result was reproduced in PBMCs isolated from two
different healthy donors in two independent experiments (data
not shown). Efforts to identify this ,130 kDa ISGylated
protein(s) using mass spectrometry failed to provide a specific
result (data not shown).
Monocytes and NK-enriched cell populations are the
major producers of ISG15 after FHA stimulation of PBMCs
Next, to identify the PBMC subset type(s) that produced ISG15
in response to FHA, PBMCs were separated into monocytes,
lymphocytes, and natural-killer (NK) cells. From each purified or
enriched cell population, 2610
6 cells were stimulated with
1,000 U/ml IFN-a or 5 mg/ml FHA-2. ISG15 mRNA abundance
was determined by real-time RT-PCR after 4, 8, and 20 hrs
(Fig. 5A); intracellular levels of ISG15 protein were evaluated by
FACS analysis after 4 hrs of stimulation (Fig. 5B).
As shown in Fig. 5A, IFN-a produced roughly comparable
levels of ISG15 transcript in PBMCs and NK-enriched cells, with
peak expression (8563 and 7365-fold respectively) at 4 hrs of
treatment. Monocytes exhibited similar expression kinetics, but at
a lower magnitude (3261-fold after 4 hrs of treatment). Lympho-
cytes were the least responsive cells with a maximum of 561-fold
change. The responsiveness to FHA treatment by the different cell
types showed the same profile. As previously observed (Fig. 3),
peak transcript levels of ISG15 were reached at 8 hrs post-
treatment, instead of 4 hrs as observed in IFN-a-treated cells.
Thus, among the mixed PBMC population, NK-enriched cells
and monocytes, but not lymphocytes, induced expression of ISG15
in response to IFN-a and FHA stimulation. ISG15 expression was
not induced in untreated cells during this experiment. Expression
of intracellular ISG15 protein followed a similar pattern (Fig. 5B):
after IFN-a stimulation, the fraction of ISG15-positive monocytes
increased from 2.3% to 36% and NK cells from 2.2% to 29.5%,
representing 15.6- and a 13.4-fold increases in ISG15-positive
cells, respectively. The fraction of ISG15-positive lymphocytes was
not affected by IFN-a treatment. Similarly, after 4 hrs of FHA
B. pertussis FHA and IFN Response
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respectively, produced ISG15, while only 2.3% and 2.2% of the
corresponding untreated cells expressed ISG15. The fraction of
ISG15-positive lymphocytes remained unchanged. These results
suggested that monocytes and NK cells are the major producers of
ISG15 upon exposure of PBMCs to FHA.
Figure 3. ISG15 and USP18 transcript abundance and levels of secreted IFN-a protein in PBMCs. PBMCs were stimulated with IFN-a at
1,000 U/ml, EcLPS at 1 mg/ml, FHA-1 and FHA-2 at 5 mg/ml, or BpeLPS at 0.1, 1, or 10 mg/ml for 1, 2, 4, 8, and 20 hrs (1 well/condition except for
untreated cells at time 0 for which 3 wells were used). After each time point, total RNA was collected and analyzed with RT-PCR using primers specific
for ISG15 (A) or USP18 (B). The fold transcript abundance change is calculated relative to levels occurring in untreated cells at the beginning of the
time course, and the average and range of fold change are displayed. The cell supernatants were collected and evaluated for the presence of IFN-a
protein using ELISA (C). IFN-a concentration was measured in pg/ml (left scale bar) and converted to U/ml (right scale bar) using the conversion factor
of ,4 pg/unit, according to the manufacturer’s instructions. Each sample was assayed twice, and the standard deviation was calculated based on the
average value of the two independent measurements.
doi:10.1371/journal.pone.0027535.g003
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Microbial adherence factors sometimes provoke complex
signalling events and downstream biological processes in host cells
following initial attachment to their target. This appears to be the
case for the dominant B. pertussis adhesin, FHA, which is secreted
in substantial quantities by this respiratory pathogen and which
appears to express a variety of immunomodulatory activities [12–
14,17]. In this study, we analyzed the genome-wide gene
expression responses of human PBMCs to purified FHA, in an
effort to appreciate better the range of activities associated with
this protein. PBMCs were selected because they encompass a
diverse repertoire of both innate and adaptive immune functions
and because of their roles in surveillance for infectious threats,
both directly, through contact with infectious agents, and
indirectly, through interactions with infected cells and tissues by
means of secreted signalling molecules [47]. Moreover, a previous
study investigated the effect of heat-killed B. pertussis on human
PBMCs at the genome wide level [20]. Our data highlight the
broad range of transcripts whose expression is affected by this
bacterial adhesin. Of interest, our study revealed significant
changes in the expression of several IFN-regulated genes,
including those associated with the type I IFN response and with
ISGylation.
We employed FHA preparations, purified using two different
methods from four B. pertussis strains, in order to recognize
conserved features of this protein and avoid strain-specific biases.
The four strains were chosen to represent both recent clinical
isolates and laboratory-adapted strains. One of the FHA
preparations has been previously used to demonstrate FHA pro-
inflammatory and pro-apoptotic activities, as well as its ability to
modulate the NF-kB pathway [12,13]. In addition, we reasonably
postulated that, if contaminants should be co-purified with FHA,
they would very likely be different and be present in different
amounts in the various preparations, leading to a heterogenous
response. Thus, our use of different preparations of FHA and the
finding of similar, if not identical, gene expression patterns
induced by them in host cells provides evidence of biological
reproducibility in the data and suggests functional homogeneity
among FHA preparations.
FHA altered the expression of 1,235 elements, representing 683
known unique genes. For most of these genes (419/683), their
expression was up-regulated, suggesting that FHA more often
activates than represses the host cell processes at the transcrip-
tional level. All but one of the 12 genes that were part of a
‘‘common host-transcriptional response’’ to bacteria mediating
inflammation [21] were also up-regulated in our data set; this
finding highlights the important contribution of cell-free FHA to
the inflammatory process associated with B. pertussis and with
whooping cough [48] since a single virulence factor can induce a
specific set of genes often reported as up-regulated by whole
bacteria, viruses, yeast, protozoa, and helminths.
The cytokines induced by FHA might indirectly promote B.
pertussis binding to host cells; IL-8, SCYA2/CCL2, GRO1/
CXCL1, TNF-a, and IFN-c, all induced at least at the
transcriptional level by FHA (and in some cases, shown at the
level of secreted protein), are known to promote expression of
CD11b/CD18 (CR3) [49–51] which may serve as a receptor for
FHA at the surface of neutrophils and monocytes [9,52]. FHA
might also influence host cell-cell interactions by up-regulating
ICAM1 at the surface of PBMCs, similar to the process that has
been observed with Mycobacterium tuberculosis [53] and Streptococcus
pneumoniae pneumolysin [54]. Taken together, these results suggest
that, in addition to acting as an adhesin, FHA influences host cell-
cell interactions and inflammatory responses. B. pertussis FHA also
affects the nature and the magnitude of the immune response that
develops during Bordetella infection, similar to the effects reported
for B. bronchiseptica FHA [17].
In addition to activating a common host transcriptional
response, FHA also induced a more specific transcriptional
program, not seen previously with heat-killed B. pertussis or B.
pertussis LPS treatment (FHA-activation cluster). There are at least
three reasons why this response may be specific to FHA and not
due to LPS contamination. First, all four FHA preparations,
independent of strain background, method of purification, and
amount of contaminating LPS (,0.2–0.45 mg/ml), induced
reproducible and consistent gene expression profiles. Second, by
comparison with Boldrick’s data set [20], we identified distinct
gene expression profiles associated with BpeLPS that were not
associated with FHA in our experiments. Third, LPS with
endotoxin activity equal to that observed in our FHA preparations
has been shown to induce a different TNF-a response [13]. We do
not believe that the trace amount of adenylate cyclase (AC) toxin
present in each FHA preparation (#0.0135 pmol/ml, correspond-
ing to approximately 2.4 ng/ml) plays any role in this observed
host response. Indeed, only high concentrations (20 ng/ml) were
recently used by Cheung et al. to evaluate the transcriptional
responses of murine macrophages to B. pertussis AC toxin [55] and
none of the genes present in our ‘‘FHA-activation cluster’’ showed
any response in the Cheung study. In addition, the concentrations
of LPS found in our FHA preparations are below the amount
Figure 4. Expression of ISG15 and ISGylated proteins in
PBMCs. PBMCs were stimulated with IFN-a (IFN) at 1,000 U/ml, EcLPS
at 1 mg/ml, BpeLPS at 10 mg/ml, or FHA-2 (FHA) at 5 mg/ml or remained
untreated for 20 hrs. Cell lysates were prepared as described in
Materials & Methods, and 90 mg of total protein was resolved with 10%
or 15% SDS-PAGE under reducing conditions. Immunoblotting was
performed with rabbit polyclonal anti-ISG15 to reveal ISG15 conjugates
(A, 10% SDS-PAGE gel) and mouse monoclonal anti-ISG15 clone 2.1 to
reveal free ISG15 (B, 15% SDS-PAGE gel). The latter membrane was re-
probed with anti-actin antibody to assess protein loading (C). Where
indicated, 20 ng purified ISG15 was resolved. Relative mobility of
molecular weight markers is indicated to the left of the figure. The
arrow points to an ISGylated protein of ,130 kDa in FHA-treated cells.
doi:10.1371/journal.pone.0027535.g004
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[56], for proliferation/IL-2 secretion from peripheral blood
lymphocytes [57], for inducing cytotoxicity in J774 cells, and for
increased cAMP production in J774 cells [58]. The reason for
obtaining a FHA-specific transcriptional program not observed
after treatment with heat-killed B. pertussis, might simply be
explained by the fact that, in our study, the amount of FHA used
to treat the cells is higher than the amount of FHA present in a
bacterial suspension. Alternatively, FHA might have been affected
by the heat treatment, supported by the fact that heat-inactivation
of FHA suppress its ability to agglutinate red blood cells. A third
explanation could be that, in the presence of other bacterial
components (such as those in a bacterial suspension), the
transcriptional changes induced by FHA might be diminished by
other bacterial components.
The most notable feature of this FHA-specific activation cluster
was that 69% (9/13) of the identified genes are known to be
regulated by IFN. Moreover, 18.3% (125 of 683 known unique
genes) of all FHA-responsive genes are IFN-regulated. Among
these were the genes encoding the major antiviral proteins PKR,
Figure 5. ISG15 mRNA expression and intracellular protein production in PBMCs and cell subsets. PBMCs were separated into
monocytes (Mono), lymphocytes (Lympho), and an NK-enriched cell population (NK), using magnetic beads. (A) For ISG15 mRNA expression, 2610
6
cells/ml were cultured for 4, 8, and 20 hrs in the presence of IFN-a (IFN-a-treated cells) at 1,000 U/ml or FHA-2 (FHA-treated cells) at 5 mg/ml or
without treatment. At each time point, total RNA was extracted and analyzed by RT-PCR. The fold expression change shown in the Figure is relative to
levels in untreated cells at the beginning of the time course; the standard deviations for duplicate measurements are displayed. (B) For intracellular
detection of ISG15, monocytes, NK-enriched cells, and lymphocytes were stimulated for 4 hrs with IFN-a (IFN-a-treated cells) at 1,000 U/ml or FHA-2
(FHA-treated cells) at 5 mg/ml or without treatment. Cells were then stained for intracellular ISG15 using the mouse monoclonal anti-ISG15 clone 4.1
labeled with AlexaFluor 647 (AF647). The number in the upper left corner of each graph represents the percentage of total cells testing positive for
ISG15.
doi:10.1371/journal.pone.0027535.g005
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finding suggested that FHA activates a host IFN type I response.
In fact, FHA induces IFN-a secretion by PBMCs. While B. pertussis
is known to induce the production of IFN-c [59], the expression of
a type I IFN (IFN-b) has only recently been reported, in human
monocyte-derived dendritic cells infected with an adenylate
cyclase-deficient B. pertussis strain [60]. To our knowledge, our
work is the first to reveal induction of a strong IFN and IFN type I
response by FHA, and one of the first to report a type I IFN
response to a secreted bacterial virulence factor.
Type I IFNs are potent antiviral immunoregulators that also
play a fundamental role in the host response to bacterial infections
[36]. Several bacteria induce production of type I IFNs by infected
cells or in infected mice; in the case of L. monocytogenes, activation of
type I IFN signaling induces apoptosis of splenic cells, which
contributes to the virulence of the infection. Because FHA-induced
apoptosis in human cells is only partly dependent on the
production of TNF-a [13], we hypothesize that the FHA-induced
type I IFN response might contribute to cell death. It might thus
represent an additional mechanism for rendering the host more
susceptible to infection.
An intriguing feature of the FHA-induced IFN type I response
is the upregulation of several members of the ISGylation
pathway: the ubiquitin-like protein ISG15, its specific isopepti-
dase USP18, and the ISG15-activating enzyme UBE1L. ISG15 is
rapidly and strongly induced in response to stimulation by type I
IFN [61] and by certain types of LPS [62]. In human PBMCs,
ISG15 transcript abundance increases after stimulation with heat-
killed E. coli, but not S. aureus, B. pertussis,o rB. pertussis LPS [20].
Although we confirmed that BpeLPS was only a weak inducer of
ISG15 mRNA, we demonstrated that purified FHA induced high
levels of ISG15 mRNA, as well as increased levels of free ISG15
and several ISGylated conjugates. The presence of an additional
conjugate of ,130 kDa in FHA-treated cells suggests that FHA
might modify the function of at least one target protein in the
host. However, because multiple molecules of ISG15 may
conjugate to the same protein [26], the actual size of the target
protein may be difficult to predict a priori; further investigation
will be needed to identify the targets of ISGylation resulting from
FHA exposure.
Our study demonstrated that monocytes and an NK-enriched
cell population were, in contrast to lymphocytes, the main
producers of ISG15, both at the mRNA and protein levels. These
results not only are consistent with earlier findings [63], but they
also reveal that NK cells are not only the target of ISG15 [63], but
also one of the major producers of ISG15, suggesting autocrine
regulation of ISG15 in NK cells. This seems to be a feature of the
ISGylation pathway, independent of the stimulus.
The peak levels of ISG15 (and USP18) transcript abundance
were consistently observed after 8 hours of FHA exposure, rather
than after 4 hours, as is the case after EcLPS and IFN-a treatment.
These findings suggested two hypotheses. First, FHA might delay,
and then amplify the expression of ISG15 and USP18 through
typical pathways and mechanisms. Alternatively, FHA might use a
different signaling pathway that results in delayed expression of
these genes. In any case, the late induction of ISG15 expression
could be responsible for the late inhibition of NF-kB activation
[12] due to the negative regulation of this pathway by ISGylation
[64].
ISG15 interferes with ubiquitination of viral proteins [31,32]
and exhibits cytokine-like immunomodulatory activities [45,46]. In
addition, USP18 was recently identified as a novel regulator of
IFN signaling [42]. Even though it is now clear that ISG15 has the
capacity to modulate diverse cellular and physiologic functions, the
roles of ISG15 and the ISGylation pathway in host defense against
infectious agents have not been fully elucidated [65]. We believe
that our work, by broadening our awareness of the involvement of
this pathway in bacterial infection, might contribute to an
understanding of the ‘‘ubiquitin-like enigma’’ [24], and help
suggest mechanisms by which bacterial pathogens modulate the
host immune response.
Materials and Methods
Bacterial strains, bacterial products, and culture
conditions
Clinical isolates, laboratory strains, and isogenic mutant strains
of B. pertussis (Table 1) were cultured in modified Stainer-Sholte
medium (SSM) [66] or on Bordet-Gengou (BG) agar (Difco
Laboratories, Detroit, MI) plates supplemented with 13% vol/vol
whole sheep blood (Microbiological Media, Concord, CA) in the
presence of antibiotic(s) when appropriate. E. coli Sm10l-pir [67]
was grown in Luria Bertani (LB) broth or on LB agar plates.
Antibiotics (Sigma, St Louis, MO) were used at the following
concentrations: ampicillin, 200 mg/ml; nalidixic acid, 50 mg/ml;
rifampicin, 30 mg/ml; streptomycin, 100 mg/ml; gentamicin,
50 mg/ml. E. coli O111:B4 LPS was purchased from Sigma, and
B. pertussis LPS was a generous gift from A. Preston (Department of
Molecular and Cellular Biology, University of Guelph, Ontario,
Canada).
Table 1. B. pertussis Strains Used in This Study.
Name Parental strain Genotype or Relevant Characteristic Reference/Source
Bpe52 Clinical isolate (1994), Gm
R,R i f
R [83]
BP338 Tohama I Lab strain (1983), Gm
R,N a l
R [84]


























R, Dptx-ptl This work
Rif: rifampicin; Nal: nalidixic acid; Sm: streptomycin; Gm: gentamicin.
doi:10.1371/journal.pone.0027535.t001
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To prevent co-purification of pertussis toxin with FHA, the
entire ptx-ptl region was deleted from Bpe136 (Sm
R derivative of
BP338), Bpe144 (Sm
R derivative of Minnesota 1), and Bpe146
(Sm
R derivative of Bpe52) by homologous recombination, as
previously described [68]. Plasmid pDMC28 (a generous gift from
D. L. Burns, Division of Bacterial, Parasitic, and Allergenic
Products, Center for Biologics Evaluation and Research, Food and
Drug Administration, Bethesda, Maryland, USA) was transformed
into E. coli Sm10l-pir. Allelic exchange was performed on BG-
agar plate for 4 hours between E. coli Sm10l-pir (pDMC28) and
B. pertussis (Bpe136, Bpe144, or Bpe146). Co-integrants were
selected for their resistance to both gentamicin and nalidixic acid
or rifampicin, and their sensitivity to streptomycin. Loss of the
plasmid by homologous recombination was selected by sequen-
tially plating the colonies on BG agar containing streptomycin,
and then BG agar containing gentamicin. The absence of the ptx
and ptl genes was confirmed by PCR using primers annealing at
positions 3991407–3991430 and 3991407–3991430 of the assem-
bled B. pertussis sequences from the Sanger Centre (www.sanger.ac.
uk), between ptlA and ptlB. Absence of pertussis toxin was verified
by Western-blot using a monoclonal antibody against the S1
subunit (m1B7, a generous gift from J. Maynard, Department of
Chemical Engineering and Materials Science, University of
Minnesota, MN, USA) (data not shown).
Cell separation and culture
Human PBMCs were purified from freshly drawn blood or from
the ‘‘buffy coat’’ fraction from healthy donors (Stanford Blood
Center, Stanford, CA), using Ficoll-Paque (Amersham Biosciences,
Piscataway, N.J.) according to the manufacturer’s instruction.
PBMCs were resuspended in RPMI-1640 medium (American
Type Culture Collection, ATCC, Manassas, VA) supplemented
with 10% fetal bovine serum (ATCC), 100 U/ml penicillin, and
100 mg/ml streptomycin (Gibco, Invitrogen Corportation, Carls-
bad, CA).
For some experiments, PBMCs were further separated into
natural killer (NK) cells, monocytes, and lymphocytes using
magnetic cell separation (Miltenyi Biotec, Auburn, CA). NK cells
were first positively enriched from PBMCs using the CD56
MicroBeads kit. The monocytes and lymphocytes present in the
flow-through were further separated using the Monocyte Isolation
Kit II; the resulting CD14+ cells were 81% pure. (CD14 antigen is
expressed at high levels on monocytes. In addition, anti-CD14
antibody recognizes interfollicular macrophages, reticular dendrit-
ic cells, and some Langerhans cells [BD Biosciences]). CD3+ and
CD20+ cells were 86% pure. (The anti-CD3 antibody recognizes a
major subset of peripheral blood lymphocytes, but not monocytes
or granulocytes [BD Biosciences]. CD20 phosphoprotein is found
on circulating peripheral blood B lymphocytes [BD Biosciences].)
The NK-enriched fraction contained 52% CD16+ cells, as
evaluated by FACS analysis. (CD16 is expressed on NK cells, as
well as on macrophages and granulocytes [BD Biosciences].)
FHA purification
FHA was purified, as previously described [69], from B. pertussis
Bpe160, Bpe162, and Bpe163 and named FHA-2, FHA-3, and
FHA-4, respectively. Briefly, B. pertussis liquid cultures were
harvested when the optical density at 600 nm was between 2.5
and 4. The culture supernatant was supplemented with Complete
Protease Inhibitor (Roche, Indianapolis, IN) and applied at 2 ml/
min on a 5 ml HiTrap Heparin column (Amersham Biosiciences).
Purification was performed using an FPLC system equipped with a
P-500 pump and a FRAC-P100 fraction collector (Pharmacia
LKB). FHA was eluted at 2 ml/min with 16 PBS, 0.5 M NaCl
(‘‘Mock-2’’). Total protein concentrations, determined by the BCA
test (Pierce, Rockford, IL), were 560, 300, and 340 mg/ml for
FHA-2, FHA-3, and FHA-4, respectively. FHA-1 (a kind gift from
M. Pizza and R. Rappuoli, Novartis Vaccines, Siena, Italy) was
isolated from B. pertussis Wellcome 28 (W28) [70] using Matrex
Cellufine Sulfate (Millipore) and stored in a solution containing
50% glycerol, 0.5 M NaCl, and 25 mM Na2HPO4 (‘‘Mock-1’’).
The in-house FHA preparations (FHA-2, -3, and -4) were
evaluated for the presence of adenylate cyclase (AC) toxin using
ELISA [71], and for the presence of LPS using the purpald assay
[72] (data not shown). Trace amounts of AC (#2.7 pmol/mg of
total protein) and LPS (#27 mg/ml) were found in all of the FHA
preparations. After dilution of the FHA preparations into cell
cultures to obtain the working concentration (5 mg/ml), the
maximum effective LPS and AC concentrations during our
experiments never exceeded 0.45 mg/ml and #0.0135 pmol/ml
respectively. Purity of the FHA preparations was evaluated by
Coomassie blue staining and Western-blot analysis using anti-FHA
antibodies. Functionality of the FHA preparations was investigated
using a hemagglutination assay and was found to be retained as
compared to both heat-inactivated and proteinase-K-treated FHA
preparations (Fig. S1). The FHA-1 preparation was used as a
reference, as it was previously shown to induce both pro-
inflammatory and pro-apoptotic responses in human cells [13]
and to modulate the NF-kB pathway [12].
cDNA microarray and hybridization
Total RNA was extracted from PBMC using Trizol-LS
(Invitrogen), and then amplified using the MessageAmp aRNA
Kit (Ambion, Austin, TX) according to the manufacturer’s
instructions. Fluorescently labelled cDNA was hybridized to a
human cDNA microarray [73] in a two-color comparative format,
with the experimental samples labelled with Cy5 (Amersham
Biosciences) and a reference pool of mRNA (Universal Human
Reference RNA, Stratagene, La Jolla, CA) labelled with Cy3
(Amersham Biosciences). The array used for these studies
contained 37,632 spots derived from cDNA clones representing
approximately 18,000 unique human genes and was previously
used in a variety of published studies [39,74–78].The labelling
reaction, and microarray hybridization and washing were
performed as previously described (http://cmgm.stanford.edu/
pbrown/protocols/4_human_RNA.html), with the following
modifications: we used 4 mg of amplified RNA to anneal with
10 mg pd(N)6 random hexamers (Amersham Biosciences), and
hybridization was performed for 16 hours at 65uC.
Data filtering and analysis
Arrays were scanned using a GenePix 4000b microarray
scanner (Axon Instruments, Foster City, CA), and image analysis
was performed using GenePix Pro version 5.0 (Axon Instruments).
Data were expressed as the log2 ratio of background-subtracted
fluorescence intensities from the sample versus the reference, for
each element on the array [79]. Data were filtered to retain only
the elements with a signal/background intensity ratio .2.5 (in
either sample or reference channel) in at least 80% of the 23
arrays, and with a regression correlation coefficient between
sample and reference signal .0.6. Using these criteria, we
identified 25,867 well-measured elements. The time course data
from each treatment were normalized to the averaged time-zero
data of four replicates. The data were hierarchically clustered
using the CLUSTER program [80], and displayed using TREE-
VIEW (http://rana.lbl.gov/EisenSoftware.htm).
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Total RNA was purified using the RNeasy mini kit (QIAGEN,
Valencia, CA), and 200 ng was submitted to cDNA synthesis using
TaqMan RT reagents (Applied Biosystems [ABI], Foster City, CA)
followed by PCR using the Taqman expression assays (ABI) for
USP18, ISG15, and 18S rRNA according to the manufacturer’s
instructions on the ABI Prism 7900HT sequence detection system
(ABI). At the beginning of each time course experiment (time
zero), total RNA from untreated cells (two or three independent
wells) was also extracted and used as the reference for comparison
with the expression level of treated cells using the comparative CT
method [81]. Within each experiment, the PCR product of each
sample was measured in duplicate; the mean, as well as the range
of fold change are displayed on the graph.
Western-blot analysis
A total of 5610
7 PBMCs were stimulated with 1,000 U/ml IFN-
a (Biosource, Camarillo, CA), 1 mg/ml EcLPS, 10 mg/ml BpeLPS,
or 5 mg/ml FHA-2, or left untreated for 20 hours. Cell lysates were
prepared accordingto a protocol adapted from D’Cunha et al. [82].
PBMCs were washed and resuspended into 500 to 800 ml cold lysis
buffer (0.02 M Tris-Cl pH 7.5, 0.15 M NaCl, 0.5% deoxycholate,
0.5% triton X-100, 0.05% SDS, 0.01 M EDTA, and 16solution of
Complete Protease Inhibitor [Roche]). After incubation on ice for
30 min, cells were passed through a 21-gauge needle and
centrifuged for 20 min at 12,0006g at 4uC. The protein
concentration was determined using MicroBCA (Pierce), and
90 mg were loaded onto 10% (for separation of ISGylated proteins)
or 15% (for separation of free ISG15) SDS-polyacrylamide gels and
transferred to Immobilon-P PVDF membrane (Millipore Corpora-
tion, Bedford, MA). ISGylated proteins were detected with a 1/500
dilution of rabbit-anti-human ISG15 IgG (Rockland, Gilbertsville,
PA); free ISG15 was detected using a 1/1,000 dilution of mouse
monoclonal anti-human ISG15 (clone 2.1; a kind gift from E.
Borden, Cleveland Clinic Foundation, Cleveland, OH). Anti-
human ISG15 antibodies were detected with HRP-conjugated
goat-anti rabbit (1/10,000, Sigma), or with anti-mouse (1/5,000,
Sigma) antibodies. Blots were visualized using the ECL-Plus
Western blotting detection kit according to the manufacturer’s
instructions (Amersham Biosciences). To assess equal protein
loading, membranes used for the detection of free ISG15 were
stripped and re-probed with a 1/1,000 dilution of mouse
monoclonal anti-actin antibody (Lab Vision Corporation, Fremont,
CA) and a 1/5,000 dilution of anti-mouse secondary antibody
(Sigma). As a positive control, 20 ng human recombinant ISG15
(BostonBiochem, Cambridge, MA) was loaded on all gels. The
higher molecular weight of recombinant ISG15 compared to
endogenous ISG15 is due to an extra amino acid left after cleavage
of a GST tag from the recombinant protein.
Cytokine measurement by ELISA and Luminex assay
Detection of IFN-a in the supernatant of cultured PBMCs was
performed using the Human Interferon Alpha (Hu-IFN-a) ELISA
kit (Biosource International, Inc., Camarillo, CA) according to the
manufacturer’s instructions. Each sample was measured twice in
duplicate and the standard deviation was calculated based on the
average value of the two independent measurements.
Samples with supernatant were sent to an outside laboratory,
Upstate (Charlottesville, VA) for measurements of TNF-a, IL-1b,
IL-6, and IL-8 concentration using the Beadlyte Human Cytokine
Profiler Analysis (Upstate). The results reported were the average
of triplicate measurements.
FACS analysis
Flow cytometry was performed at the Stanford University
Digestive Disease Centre Core Facility (VA Hospital, Palo Alto,
CA, USA) using the BD LSR II system (BD Biosciences, San Jose,
CA). For each sample, a minimum of 100,000 events were
collected. Data were analysed with FACSDiva software (BD
Biosciences).
For cell surface staining, approximately 1610
6 cells were
washed and incubated with 10% human serum before staining
with one of the following FITC- or PE-conjugated antibodies
(Caltag Laboratories, Burlingame, CA, and BD PharMingen):
CD3, CD20, CD14, and CD16. After staining, cells were washed
once and fixed with 1% paraformaldehyde.
For the detection of intracellular ISG15, cells were incubated
for 4 hours with stimulus, and in the presence of 10 mg/ml
brefeldin A (Sigma) during the last 2 hours. Approximately 1610
6
cells were washed, resuspended in 10% human serum for 20 min
on ice, washed, and resuspended in 2% paraformaldehyde. After
20 min incubation on ice, cells were washed and resuspended in
PBA buffer (0.2% BSA and 0.09% sodium azide in 16PBS). After
overnight incubation at 4uC, cells were resuspended in 10 ml
saponin buffer (0.2% BSA and 0.5% saponin in 16 PBS)
containing 10 mg mouse IgG (Jackson ImmunoResearch, West
Grove, PA) to block nonspecific binding; Alexa Fluor 647-
conjugated mouse monoclonal anti-ISG15 or Alexa Fluor 647-
conjugated mouse IgG antibodies were then added to monitor
nonspecific binding. After 15 min incubation on ice and washing
with cold saponin buffer, cells were resuspended in 500 ml PBA
buffer for analysis. Alexa Fluor 647-conjugated antibodies were
obtained by labelling 100 mg of mouse monoclonal anti-ISG15
antibody (clone 4.1, a generous gift from Dr. E. Borden, Cleveland
Clinic Foundation, Cleveland, OH) and 100 mg of purified mouse
IgG1 (eBioscience, San Diego, CA) using the Alexa Fluor 647
monoclonal antibody labelling kit (Molecular Probes, Eugene,
OR) according to the manufacturer’s instructions.
Microarray data deposition
The data discussed in this publication have been deposited at
NCBI Gene Expression Omnibus (GEO, http://www.ncbi.nlm.
nih.gov/geo) and are available through GEO Series accession
number GSE8802.
Supporting Information
Figure S1 Integrity and functionality of FHA purified
from B. pertussis culture supernatants. FHA was purified
from B. pertussis culture supernatant as described in Materials and
Methods. A. Total protein concentration in FPLC elution
fractions 4–8 of Bpe160 (FHA-2), Bpe162 (FHA-3), and Bpe163
(FHA-4). B. Coomassie blue staining of Bpe160 (160) and Bpe163
(163) liquid culture supernatants (loaded with the equivalent of
400 ml liquid culture at OD600 nm=3), as well as their
corresponding purified, FHA-2 (10 ml fraction #5) and FHA-4
(34 ml of fraction #5). Protein size in kDa of the molecular weight
markers (MW) is indicated on the left. C. Western-blot analysis of
FHA-1 using anti-FHA antibody (M08), with protein size (kDa)
indicated on the right. D. Agglutination with FHA-1, as well as
FHA-2 (elution fractions #9 (193 mg protein/ml), #10 (1200 mg
protein/ml), #11 (821 mg protein/ml), and #12 (373 mg protein/
ml) from a purification similar to that shown in A) was performed
by adding 50 ml FHA to 50 ml 1% sheep blood and incubating for
1 h at 37uC in a V-shape bottom 96-well plate. PBS was used as
negative control and did not agglutinate the red blood cells. FHA-
1 was either heat-inactivated for 20 minutes at 95uC (heat) or
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before incubation with red blood cells.
(TIF)
Table S1 FHA-activated elements. The 817 elements whose
expression was activated by at least 3-fold in FHA-treated
compared to untreated cells are represented, together with their
expression values.
(XLS)
Table S2 FHA-repressed elements. The 418 elements
whose expression was repressed by at least 3-fold in FHA-treated
compared to untreated cells are represented, together with their
expression values.
(XLS)
Table S3 IFN-regulated genes whose expression is
affected by FHA treatment. The IFN-regulated genes were
selected from the 1,235 FHA-responsive elements by comparison
with lists of known IFN-a-, -b-, and -c-regulated genes [36–40].
This comparison returned 296 elements.
(XLS)
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